Avacopan is a potent, selective, orally availale C5aR (CD88) inhibitor with IC50 of 0.1 nM.

A novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2.

Omidenepag Isopropyl (DE-117, OMDI) is the prodrug of Omidenepag, which is a potent, selective agonist human EP2 receptor; demonstrates excellent IOP-lowering activities following ocular administration in ocular normotensive monkeys, Omidenepag Isopropyl (OMDI) is a clinical candidate for the treatment of glaucoma.

Benzbromarone is a highly effective and well tolerated non-competitive inhibitor of xanthine oxidase, used as an uricosuric agent, used in the treatment of gout.

Acebilustat(ZK322) is a potent and selective leukotriene A4 hydrolase inhibitor.

Acrizanib（LHA510） is a potent and selective angiogenesis inhibitor and VEGFR‑2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.

CB-03-01 is a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use.

RTA-408 is a synthetic triterpenoid that potently activates the antioxidative transcription factor Nrf2 and inhibits the proinflammatory transcription factor NF-κB.

Fulacimstat(BAY 1142524) is a small molecule chymase inhibitor.

GLPG-1837(ABBV-974) is a novel cystic fibrosis transmembrane conductance regulator CFTR potentiator.

For the detailed information of Vonoprazan, the solubility of Vonoprazan in water, the solubility of Vonoprazan in DMSO, the solubility of Vonoprazan in PBS buffer, the animal experiment (test) of Vonoprazan, the cell expriment (test) of Vonoprazan, the in vivo, in vitro and clinical trial test of Vonoprazan, the EC50, IC50,and affinity,of Vonoprazan, For the detailed information of Vonoprazan, the solubility of Vonoprazan in water, the solubility of Vonoprazan in DMSO, the solubility of Vonoprazan in PBS buffer, the animal experiment (test) of Vonoprazan, the cell expriment (test) of Vonoprazan, the in vivo, in vitro and clinical trial test of Vonoprazan, the EC50, IC50,and affinity,of Vonoprazan, Please contact DC Chemicals..

Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation.

LAU159 is a novelα6β3γ2 GABAA receptor inhibitor.

Lusutrombopag（S-888711） is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.

Methylnaltrexone Bromide is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation.

Mosapride citrate is a gastroprokinetic agent that acts as a selective 5HT4 agonist.

Rho-kinase (ROCK) inhibitor

Pramiracetam

PBI-4050 (Setogepram, PBI4050) is a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively.

PBI-4050 (Setogepram, PBI4050) is a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively.

Pantoprazole sodium salt(SKF96022; Protonix) is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Olumacostat glasaretil is a small molecule inhibitor of acetyl coenzyme A carboxylase (ACC).

Olacaftor (VX-440, VX440) is a next-generation CFTR corrector, showsthe potential to enhance the amount of CFTR protein at the cell’s surface and for treatment of cystic fibrosis..

NKP608 is a non-peptidic derivative of 4-aminopiperidine which acts as a selective, specific and potent antagonist at the neurokinin-1 (NK-1) receptor both in vitro(IC50=2.6 nM) and in vivo.

Nepafenac

Mozavaptan (OPC31260) is a orally effective, nonpeptide vasopressin V2 receptor antagonist with an IC50 of 14 nM.

iOWH032 is a novel and potent CFTR inhibitor (IC50=1.01 uM) in T84 and CHO-CFTR cell based assays.

Fonadelpar (NPS-005,SJP-0035) is a potent, selective peroxisome proliferator activated receptor δ (PPARδ) agonist for the treatment of corneal disorders..

EPI-743 (Vatiquinone,EPI-589) is an orally bioavailable para-benzoquinone for treatment of inherited mitochondrial diseases, an analogue of the antioxidant ubidecarenone.